GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Price-to-Owner-Earnings

SCYNEXIS (LTS:0L49) Price-to-Owner-Earnings : 2.73 (As of May. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Price-to-Owner-Earnings?

As of today (2024-05-14), SCYNEXIS's share price is $2.10. SCYNEXIS's Owner Earnings per Share (TTM) ended in Mar. 2024 was $0.77. It's Price-to-Owner-Earnings for today is 2.73.


The historical rank and industry rank for SCYNEXIS's Price-to-Owner-Earnings or its related term are showing as below:

LTS:0L49' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.83   Med: 2.15   Max: 2.83
Current: 2.56

During the past 12 years, the highest Price-to-Owner-Earnings of SCYNEXIS was 2.83. The lowest was 1.83. And the median was 2.15.


LTS:0L49's Price-to-Owner-Earnings is ranked better than
97.62% of 420 companies
in the Drug Manufacturers industry
Industry Median: 28.12 vs LTS:0L49: 2.56

As of today (2024-05-14), SCYNEXIS's share price is $2.10. SCYNEXIS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $2.02. Therefore, SCYNEXIS's PE Ratio for today is 1.04.

As of today (2024-05-14), SCYNEXIS's share price is $2.10. SCYNEXIS's EPS without NRI for the trailing twelve months (TTM) ended in was $1.53. Therefore, SCYNEXIS's PE Ratio without NRI for today is 1.38.

During the past 12 years, SCYNEXIS's highest PE Ratio without NRI was 3.38. The lowest was 1.00. And the median was 1.37.


SCYNEXIS Price-to-Owner-Earnings Historical Data

The historical data trend for SCYNEXIS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Price-to-Owner-Earnings Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.94

SCYNEXIS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.60 2.94 -

Competitive Comparison of SCYNEXIS's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Price-to-Owner-Earnings falls into.



SCYNEXIS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

SCYNEXIS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.10/0.77
=2.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCYNEXIS  (LTS:0L49) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


SCYNEXIS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines